Development of Online EMDR Therapy System and Its Comparative Testing With Face-to-Face EMDR Therapy for Treatment of Anxiety and Depressive Disorders in Pakistan
Development of Online EMDR Therapy System and Its Comparative Testing With Face-to-Face EMDR Therapy for Treatment of Anxiety and Depressive Disorders in Pakistan: A Randomized Controlled Feasibility-Pilot Study*
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Khyber Pakhtunkhwa
-
Lakki Marwat, Khyber Pakhtunkhwa, Pakistan, 28420
- Kushal Khan University
-
Contact:
- Anwar Khan, PhD
- Phone Number: +92334560433
- Email: akpashtoon1981@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Both male and female patients.
- Patients between the age of 18 to 50 years (since this study is neither on children nor on old patients).
- Patients who have basic knowledge & skills of computer, mobile and internet (although the recruited patients will be given training for using the online EMDR).
- Patients do not suffer from severe neuropsychological and cognitive impairments.
- Patients have not received any pharmacological therapy in the last three months.
- Patients have not received any other psychotherapy like Cognitive Behavioral Therapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Face to Face Eye Movement Desensitization & Reprocessing Therapy
The standard Face to Face Eye Movement Desensitization & Reprocessing Therapy will be applied by a trained clinical psychologist through in person face to face sessions.
|
The Face to Face Eye Movement Desensitization & Reprocessing Therapy will be delivered in person inside clinician's room by following standard EMDR therapy protocol
|
|
Active Comparator: Online Eye Movement Desensitization & Reprocessing Therapy
The Online Eye Movement Desensitization & Reprocessing Therapy will be applied by a trained clinical psychologist through computer system by connecting through internet.
For this purpose the online EMDR therapy application software will be installed
|
Online EMDR Therapy System will be delivered through online computer system that will be specifically designed for delivering EMDR therapy online
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Assessing changes in symptom of Generalized Anxiety Disorder with time (i.e., treatment course)
Time Frame: A total of 40 patients will be selected. Symptoms will be screened for 06 months in such a way that symptoms will be assessed first during base line (T1), then during mid of treatment (T2), and finally at the end of treatment (T3)
|
Generalized Anxiety Disorder by Generalized Anxiety Disorder Questionnaire-IV.
Score of 5.7 or above will indicate that the patient is suffering from Generalized Anxiety Disorder.
|
A total of 40 patients will be selected. Symptoms will be screened for 06 months in such a way that symptoms will be assessed first during base line (T1), then during mid of treatment (T2), and finally at the end of treatment (T3)
|
|
Assessing changes in symptom of Major Depressive Disorder with time (i.e., treatment course)
Time Frame: A total of 40 patients will be selected. Symptoms will be screened for 06 months in such a way that symptoms will be assessed first during base line (T1), then during mid of treatment (T2), and finally at the end of treatment (T3)
|
Major Depressive Disorder by Beck Depression Inventory-II.
Score of 30 or above will indicate that the patient is suffering from major depressive disorder
|
A total of 40 patients will be selected. Symptoms will be screened for 06 months in such a way that symptoms will be assessed first during base line (T1), then during mid of treatment (T2), and finally at the end of treatment (T3)
|
|
Assessing changes in symptom of Social Anxiety Disorder with time (i.e., treatment course)
Time Frame: A total of 40 patients will be selected. Symptoms will be screened for 06 months in such a way that symptoms will be assessed first during base line (T1), then during mid of treatment (T2), and finally at the end of treatment (T3)
|
Social Anxiety Disorder will be assed by Social Anxiety Scale.
Score of 60 or above will indicate that the patient is suffering from Social Anxiety Disorder.
|
A total of 40 patients will be selected. Symptoms will be screened for 06 months in such a way that symptoms will be assessed first during base line (T1), then during mid of treatment (T2), and finally at the end of treatment (T3)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Assessing changes in Panic symptoms with time (i.e., treatment course)
Time Frame: A total of 40 patients will be selected. Symptoms will be screened for 06 months in such a way that symptoms will be assessed first during base line (T1), then during mid of treatment (T2), and finally at the end of treatment (T3)
|
Panic Attacks by Panic Disorder Severity Scale.
Score of 20 or above will indicate that the patient is suffering form panic symptoms.
|
A total of 40 patients will be selected. Symptoms will be screened for 06 months in such a way that symptoms will be assessed first during base line (T1), then during mid of treatment (T2), and finally at the end of treatment (T3)
|
|
Assessing changes in Somatic symptoms
Time Frame: A total of 40 patients will be selected. Symptoms will be screened for 06 months in such a way that symptoms will be assessed first during base line (T1), then during mid of treatment (T2), and finally at the end of treatment (T3)
|
Somatic Symptoms by the Somatic Symptom Scale-8.
Score of 11 or above will indicate that the patient is suffering from somatic symptoms.
|
A total of 40 patients will be selected. Symptoms will be screened for 06 months in such a way that symptoms will be assessed first during base line (T1), then during mid of treatment (T2), and finally at the end of treatment (T3)
|
|
Assessing changes in Obsessive symptoms with time (i.e., treatment course)
Time Frame: A total of 40 patients will be selected. Symptoms will be screened for 06 months in such a way that symptoms will be assessed first during base line (T1), then during mid of treatment (T2), and finally at the end of treatment (T3)
|
Obsessive Compulsive Symptoms by Dimensional Obsessive-Compulsive Scale.
Score of 15 or above on each dimension will indicate that the patient is having Obsessive Compulsive Symptoms.
|
A total of 40 patients will be selected. Symptoms will be screened for 06 months in such a way that symptoms will be assessed first during base line (T1), then during mid of treatment (T2), and finally at the end of treatment (T3)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 12321
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.